Key points are not available for this paper at this time.
A record PCE of ∼9.5% is achieved for a P3HT-based non-fullerene OSC with enhanced VOC and optimized phase separation morphology by modifying the end groups of the NFA, ZY-4Cl.
Yang et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: